Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* patients with visceral leishmaniasis characterized by fever plus hepatomegaly or splenomegaly with at least one positive result in the following laboratory tests:~* direct observation of leishmania amastigotes in bone marrow smear~* leishmania in vitro culture from bone marrow aspirates~* leishmania kDNA amplification by PCR in bone marrow or peripheral blood samples~* rK39 immunochromatographic rapid test performed on serum sample~Exclusion Criteria:~* pregnancy~* HIV infection~* chronic diseases such as diabetes mellitus,kidney, liver or cardiac diseases, schistosomiasis, malaria or tuberculosis~* immune disorders or use of drugs which interferes with the immune response~* treatment with drugs with increased risk for toxicity associated with the study drugs~* exposure to antileishmanial drugs during the past six months~* I.V. drug users~* episodes of visceral leishmaniasis relapse~* hypersensibility to the study drugs~* difficulties for accomplishing the follow-up schedule~* any of the following clinical signs of laboratory abnormalities: hepatic encephalopathy, generalized edema, toxemic individuals, severe malnutrition, jaundice, abnormal serum creatinine, bilirubin, INR \> 2,0, platelet count \< 20000/mm3

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Meglumine antimoniate (Type: ACTIVE_COMPARATOR): Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
- Liposomal Amphotericin B (Type: EXPERIMENTAL): Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
- Amphotericin B (Type: EXPERIMENTAL): Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
- Combination therapy (Type: EXPERIMENTAL): Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).